1. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Issue 6 (3rd June 2017) Authors: Seftel, Matthew D.; Kuruvilla, John; Kouroukis, Tom; Banerji, Versha; Fraser, Graeme; Crump, Michael; Kumar, Rajat; Chalchal, Haji I.; Salim, Muhammad; Laister, Rob C.; Crocker, Susan; Gibson, Spencer B.; Toguchi, Marcia; Lyons, John F.; Xu, Hao; Powers, Jean; Sederias, Joana; Seymour, Lesley; Ha... Journal: Leukemia & lymphoma Issue: Volume 58:Issue 6(2017) Page Start: 1358 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Issue 6 (2nd June 2016) Authors: Hay, Annette E.; Murugesan, Alli; DiPasquale, Ashley M.; Kouroukis, Tom; Sandhu, Irwindeep; Kukreti, Vishal; Bahlis, Nizar J.; Lategan, Johan; Reece, Donna E.; Lyons, John F.; Sederias, Joana; Xu, Hao; Powers, Jean; Seymour, Lesley K.; Reiman, Tony Journal: Leukemia & lymphoma Issue: Volume 57:Issue 6(2016:Jun.) Page Start: 1463 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗